ReviewSub-cellular biochemistry2025
Small-Molecule Inhibitors and Drug Discovery of Urea Transporters.
Review in Sub-cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urea transporters (UT) in renal tubule epithelial cells (UT-A) and vasa recta endothelial cells (UT-B) play an important role in the urine concentrating mechanism. Therefore, UTs are regarded as a potential target for diuretics, or 'urearetics', with unique mechanisms of action and clinical indications. UT inhibitors have a diuretic effect without causing disorders of electrolyte balance like classical diuretics that induce diuresis by natriuresis. This chapter delves into the screening and evaluation methods used for discovering UT inhibitors, the small molecule UT inhibitors that have been identified to date, and UT inhibitors' therapeutic effect in hyponatremic animal models. The studies on UT inhibitors as diuretics show promise for treating dilutional hyponatremia associated with conditions like congestive heart failure, cirrhosis, ascites, and nephrotic syndrome, as well as the syndrome of inappropriate antidiuretic hormone (SIADH) secretion.
Indexed as
Identifiers
40637981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.